Allogeneic hematopoietic stem cell transplant outcomes for patients with dominant negative IKZF1/IKAROS mutations

Affiliations

• ¹ Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio. Electronic address: [email protected].
• ² Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio.
• ³ Immunology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Md.
• ⁴ Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
• ⁵ Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
• ⁶ Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Inserm UMR 1163, Paris, France; Clinical Immunology Department, Hôpital Saint Louis, Assistance Publique Hôpitaux de Paris (APHP) Université Paris Diderot, Paris, France.
• ⁷ Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Inserm UMR 1163, Paris, France; University Paris Descartes Sorbonne Paris Cité, Imagine Institut, Paris, France.
• ⁸ Department of Pediatric Immunology, La Timone Hospital, Marseille, France.
• ⁹ Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, Marseille, France.
• ¹⁰ Norwegian National Unit for Newborn Screening, Oslo University Hospital, Oslo, Norway.
• ¹¹ Section of Specialized Pediatric Medicine, Oslo University Hospital, Rikshospitalet, Norway.